mDF6002
mDF6002 is a IL-12R-Fc fusion protein. mDF6002 induces sustained IFNγ production. mDF6002 exerts tumor-suppressive effects in mouse models of colon cancer and melanoma. mDF6002 can be used for research on solid tumors such as colon cancer and melanoma.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
mDF6006 (0.5 μg; i.p.; once weekly) induces partial responses in 90% of B16F10 melanoma-bearing C57BL/6J mice and drives sustained pharmacodynamic responses in both tumor and serum[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cJ mice (female, 7-9 weeks old, subcutaneous inoculation with CT26 cells, advanced large tumors averaging 815 mm3)[1]
-
Dosage:1 μg (equimolar to 1 μg rmIL-12)
-
Administration:s.c.; once weekly; 7 weeks
-
Result:Induced complete tumor regression in all 10 treated mice.
Was well tolerated with no body weight loss.
Enabled 9/10 complete responders to reject tumor rechallenge and remain tumor-free, while age-matched naive controls developed progressive tumors.
-
Animal Model:C57BL/6J mice (female, 7-9 weeks old, subcutaneous inoculation with B16F10 cells)[1]
-
Dosage:0.5 μg (equimolar to 0.5 μg rmIL-12)
-
Administration:i.p.; once weekly
-
Result:Induced partial responses in 9/10 treated mice.
Significantly improved survival compared to rmIL-12.
Significantly elevated and protracted levels of IFNγ, CXCL9, CXCL10, CCL5, and TNF-α were detected in both tumor lysates and serum at 72 hours post-dose.
Chemical Information
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)